Cortechs.ai | Predicting MCI Outcome With Clinically Available MRI And CSF Biomarkers
Cortechs.ai | Predicting MCI Outcome With Clinically Available MRI And CSF Biomarkers
RSNA 2025
Contact
  • Home
  • /
  • Resources
  • /
  • Predicting MCI Outcome With Clinically Available MRI And CSF Biomarkers

Predicting MCI Outcome With Clinically Available MRI And CSF Biomarkers

  • Category: Published research

Study to determine the ability of clinically available volumetric MRI (vMRI) and CSF biomarkers, alone or in combination with a quantitative learning measure, to predict conversion to Alzheimer’s disease (AD) in patients with mild cognitive impairment (MCI). 2011 October 12.

[button]Download[/button]

  • Topic: Published research

More Resources

Cortechs.ai | Predicting MCI Outcome With Clinically Available MRI And CSF Biomarkers
  • 2 mins

12/18/2025

Reimbursement Essentials for Quantitative Imaging: Key Takeaways From Our Expert Webinar

Our reimbursement webinar walked through best practices for billing, coding, and securing payment for NeuroQuant and OnQ Prostate, helping inform providers.

Cortechs.ai | Predicting MCI Outcome With Clinically Available MRI And CSF Biomarkers
  • 2 mins

12/10/2025

Reflections on RSNA 2025 and What We Learned at the Cortechs.ai Booth 

If there was one overall takeaway from RSNA 2025, it’s that clinicians are ready for tools that reduce manual work and make reporting more consistent.

Cortechs.ai | Predicting MCI Outcome With Clinically Available MRI And CSF Biomarkers
  • < 1 mins

12/09/2025

Dementia Imaging: Case-based PET/MRI Approach

Join us for a webinar that will unlock the latest insights in dementia imaging with Dr. Ana M. Franceschi, MD PhD.

,

Cortechs.ai | Predicting MCI Outcome With Clinically Available MRI And CSF Biomarkers
  • 2 mins

12/09/2025

SNO 2025 Recap: Collaboration Driving Innovation in Neuro-Oncology

The 2025 Society for Neuro-Oncology meeting was more than a conference, it was a hub of collaboration and conversation among industry leaders and physicians.

Cortechs.ai | Predicting MCI Outcome With Clinically Available MRI And CSF Biomarkers
  • 3 mins

11/19/2025

Philips and Cortechs.ai extend partnership to advance quantitative neuroimaging and strengthen Philips’ leadership in precision diagnostics in neurology

The companies will integrate Cortechs.ai’s advanced AI-enabled neuroimaging analytics directly into Philips’ MR systems.

,

Cortechs.ai | Predicting MCI Outcome With Clinically Available MRI And CSF Biomarkers
  • 3 mins

11/17/2025

Unlocking the Value of NeuroQuant Reports: Different Use Cases Across Clinical Practice

From neurodegeneration and demyelination to development, trauma, and seizures, NeuroQuant supports better decision‑making, communication, and patient care

View our insights
Cortechs.ai | Predicting MCI Outcome With Clinically Available MRI And CSF Biomarkers
Cortechs.ai | Predicting MCI Outcome With Clinically Available MRI And CSF Biomarkers

Empowering precision

and clarity in patient care

5060 Shoreham Place,
Ste 240, San Diego, CA 92122

Cortechs.ai | Predicting MCI Outcome With Clinically Available MRI And CSF Biomarkers
  • Solutions
  • © Cortechs.ai 2024
Scroll to Top